SCHEMBL854288

SCHEMBL854288

CCCCCc1ccnc2ncnn12

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.42
KDM4E B2RXH2 5/20 0.42
RCE1 Q9Y256 1/20 0.42
GAA P10253 4/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
GLA P06280 2/20 0.39
HTT P42858 1/20 0.39
HPGD P15428 1/20 0.38
ATM Q13315 1/20 0.38
KDM5A P29375 1/20 0.37
KDM5B Q9UGL1 1/20 0.37
TLR7 Q9NYK1 2/20 0.36
EGLN2 Q96KS0 2/20 0.35
TBXAS1 P24557 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
MDM2 Q00987 1/20 0.34
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6468861 0.81 ALDH1A1 (0.47) ALDH1A1KDM4ERCE1GAASMN1; SMN2
SCHEMBL11049763 0.75 KDM5A (0.41) ALDH1A1KDM4EKDM5AKDM5BTLR7
SCHEMBL27492787 0.74 ALDH1A1 (0.47) ALDH1A1KDM4ERCE1GAASMN1; SMN2
SCHEMBL8125129 0.74 ALDH1A1 (0.47) ALDH1A1KDM4ERCE1GAASMN1; SMN2
SCHEMBL5617361 0.74 ALDH1A1 (0.47) ALDH1A1KDM4ERCE1GAASMN1; SMN2
SCHEMBL5090716 0.74 ALDH1A1 (0.47) ALDH1A1KDM4ERCE1GAASMN1; SMN2
SCHEMBL8944106 0.74 GAA (0.45) ALDH1A1KDM4EGAASMN1; SMN2HTT
SCHEMBL8124652 0.74 KDM4E (0.51) ALDH1A1KDM4ERCE1GAASMN1; SMN2
SCHEMBL8944035 0.73 GAA (0.47) ALDH1A1KDM4EGAASMN1; SMN2HTT
SCHEMBL8944393 0.73 GAA (0.47) ALDH1A1KDM4EGAASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143262-B2 7-(3′,4′-Dialkoxyphenyl)[1,2,4]-triazolo[1,5-A]pyrimidine compounds, process for preparing thereof, and pharmaceutical composition for treating or preventing asthma, chronic obstructive pulmonary disease, arthritis, atopic dermatitis, tumor and degenerative brain diseases comprising the same KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2012-03-27 US disclosed
US-20100105704-A1 7-(3',4'-Dialkoxyphenyl)-[1,2,4]-Triazolo[1,5-A]Pyrimidine Compounds, Process for Preparing Thereof, and Pharmaceutical Composition for Treating or Preventing Asthma, Chronic Obstructive Pulmonary Disease, Arthritis, Atopic Dermatitis, Tumor and Degenerative Brain Diseases Comprising the Same KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-04-29 US disclosed
WO-2008117943-A1 7-(3',4'-DIALKOXYPHENYL)-[1,2,4]-TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS, PROCESS FOR PREPARING THEREOF, AND PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ARTHRITIS, ATOPIC DERMATITIS, TUMOR AND DEGENERATIVE BRAIN DISEASES COMPRISING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105704-A1 7-(3',4'-Dialkoxyphenyl)-[1,2,4]-Triazolo[1,5-A]Pyrimidine Compounds, Process for Preparing Thereof, and Pharmaceutical Composition for Treating or Preventing Asthma, Chronic Obstructive Pulmonary Disease, Arthritis, Atopic Dermatitis, Tumor and Degenerative Brain Diseases Comprising the Same TSLP, IL5, ADORA1 ALDH1A1 604/4885KDM4E 1889/4885RCE1 3674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.